Form 4: Aethlon Medical Director Angela Rossetti Receives RSUs

Director Angela Rossetti was granted 21,815 restricted stock units in Aethlon Medical, vesting quarterly through March 2027.

Summary

• Angela Rossetti, a Director at Aethlon Medical, acquired 21,815 shares of common stock via a Restricted Stock Unit (RSU) grant.
• The grant was valued at $2.29 per share.
• The RSUs vest in four equal quarterly installments starting June 30, 2026, and concluding March 31, 2027.
• Following this transaction, the reporting person's total direct beneficial ownership is 26,207 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting is contingent upon the reporting person's continued service with the company.

Future Outlook

The RSUs are subject to continued service requirements, with full vesting expected by March 31, 2027.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices intended to incentivize long-term oversight and alignment with shareholder value in the biotechnology sector.

Comparison to Industry Standards

• The use of time-based RSU vesting is a standard practice for board compensation in small-cap biotech firms to retain talent without immediate cash outflow.

Stakeholder Impact

• Shareholders benefit from director alignment through equity ownership.

Next Steps

• Vesting of RSUs on June 30, 2026, September 30, 2026, December 31, 2026, and March 31, 2027.

Key Dates

Keywords

Aethlon Medical, AEMD, Form 4, Insider Transaction, Restricted Stock Units, Equity Compensation